Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen Ltd. (Nasdaq: CGEN) announced participation in a virtual event to discuss data from its Phase 1 clinical trial of COM701, an innovative antibody targeting PVRIG. The findings will be presented on June 7, 2021, at the ASCO 2021 Annual Meeting. A fireside chat hosted by Truist Securities analyst Asthika Goonewardene is scheduled for June 8, 2021, featuring key executives from Compugen. The company is focused on developing cancer immunotherapy treatments, including the ongoing studies of COM701 and COM902.
Compugen Ltd. (CGEN) reported Q1 2021 financial results with a net loss of $9.9 million or $0.12 per share, an increase from a $7.1 million loss in Q1 2020. R&D expenses rose to $7.3 million, up from $4.7 million, driven by drug manufacturing and clinical activities. The company has $119.4 million in cash reserves. Upcoming milestones include data readouts for COM701 in various studies and collaboration with Bristol Myers Squibb for a Phase 1b study. Compugen aims to lead in the DNAM axis space with promising clinical data for PVRIG and TIGIT assets.
Compugen Ltd. (NASDAQ: CGEN) announced that Eran Ophir, Ph.D., Vice President of Research and Drug Discovery, will participate in the Society for Immunotherapy of Cancer's online seminar on June 29, 2021. The seminar focuses on 'The TIGIT Pathway' and is part of a series addressing key questions in cancer immunotherapy. Co-chairs include industry experts, and an interactive Q&A session will follow. Compugen, based in Israel, is developing innovative cancer therapies, including its lead anti-PVRIG antibody, COM701, currently in Phase 1 trials.
Compugen Ltd. (CGEN) announced an expansion of its research collaboration with Johns Hopkins University on a novel myeloid target discovered through its predictive computational platform. Initial preclinical studies indicate significant tumor growth inhibition upon genetic deletion of this target, potentially serving as a myeloid immunomodulator. The collaboration aims to further investigate the biological function of this target, enhancing Compugen's immuno-oncology pipeline. The CEO emphasizes the importance of early-stage programs for the company's growth and development in cancer therapies.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, will release its first quarter 2021 financial results on May 13, 2021, before U.S. markets open. A conference call will be held at 8:30 AM ET to discuss the results and provide an update. Investors can join via telephone or through a live webcast on Compugen's website. The company is advancing its lead candidate, COM701, an anti-PVRIG antibody for solid tumors, which is currently in a Phase 1 clinical study, alongside COM902, targeting TIGIT.
Compugen Ltd. (CGEN) announced an oral presentation at the ASCO 2021 Annual Meeting, scheduled for June 7, 2021. The presentation will provide updates on the ongoing Phase 1 trial of COM701, a therapeutic antibody targeting PVRIG for advanced solid tumors. Noteworthy details include the title of the oral presentation and its focus on the safety, tolerability, and preliminary antitumor activity of COM701, evaluated with or without nivolumab. The abstract will be accessible on May 19, 2021, on ASCO.org.
Compugen Ltd. (CGEN) announced the publication of preclinical data on COM902, a novel anti-TIGIT therapeutic antibody, in Cancer Immunology, Immunotherapy. Key findings show that COM902 enhances anti-tumor immune responses by blocking TIGIT, which is expressed in various solid tumors. It demonstrates no T cell depletion activity, potentially preserving immune function. The ongoing Phase 1 trial for COM902 is expected to report initial results in Q4 2021, with further studies combining it with other therapies planned for H2 2021.
Compugen Ltd. (Nasdaq: CGEN) announced the publication of a review article in Cancer Discovery discussing the DNAM-1 axis's role in cancer immunotherapy. Co-authored by Drew Pardoll, M.D., Ph.D., the article covers key molecules such as DNAM-1, TIGIT, and PVRIG, highlighting their therapeutic relevance. It also discusses the potential of combining DNAM-1 axis blockers with PD-1/L1 agents, aiming to expand treatment options for new patient populations. Compugen is conducting Phase 1 studies on its anti-PVRIG antibody, COM701, and TIGIT-targeting antibody, COM902, focusing on the clinical evaluation of these approaches.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. The presentation will be available via live webcast on Compugen's website, with an option for replay afterward. Compugen focuses on developing therapeutics for cancer immunotherapy, featuring its lead candidate COM701, which is in a Phase 1 clinical study. The company also has another candidate, COM902, targeting TIGIT, currently in a Phase 1 trial. Compugen operates from Israel and has a presence in South San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) reported its financial results for Q4 and full year 2020. Revenues for Q4 were $2.0 million, primarily from a milestone payment from AstraZeneca. R&D expenses rose to $8.1 million in Q4 and $22.8 million for the year, driven by clinical studies and manufacturing activities. The net loss for Q4 was $8.6 million, with total cash reserves at approximately $124.4 million as of year-end. Compugen is focusing on expanding clinical programs for its immunotherapy candidates, showcasing encouraging data for COM701 in refractory cancer patients.